Skip to content

Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study

Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05612893
Acronym
DISPLAY
Enrollment
1000
Registered
2022-11-10
Start date
2022-11-16
Completion date
2025-09-10
Last updated
2022-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza, Sepsis, Upper Respiratory Tract Infection, Viral Pneumonia

Brief summary

The goal of this observational study is to describe the immune signature of acute pulmonary infection.The main questions it aims to answer are: 1. Nasal mucosal immune response in patients with influenza infection 2. Difference of immune response between Viral sepsis and Bacterial sepsis 3. Immunological differences between Viral sepsis and Viral pneumonia

Detailed description

1. Aging could influence host immune response. Elderly people are more likely to progress to severe pneumonia than young people. Nasal mucosa is the initial infection site of influenza infection. Single cell sequencing of nasal mucosal cell that may provide valuable insights into host response to influenza infection. 2. Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Although bacteria are considered as the main pathgens of sepsis,SARS-CoV-2 or influenza infection also can cause multiple organ dysfunction which meet the definition of Sepsis 3.0. Viral sepsis has not received enough attention for a long time. It is important to understand the difference between viral sepsis and bacterial sepsis that may help to develop better strategies to diagnose and treat sepsis. 3. Viral pneumonia is one of the leading infectious cause of death woldwide.Pneumina is the most common cause of sepsis.The mechanism of viral pneumonia progressing to sepsis needs to be further investigated.

Interventions

OTHERpathogen

The patients were divided into groups according to the pathogen(bacteria or virus). The influenza upper respiratory tract infection cohort will be grouped mainly according to age.

Sponsors

Capital Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age ≥18 years at time of signing Informed Consent Form 2. chest imaging confirmed pneumonia. 3. Informed consent is obtained 4. The pneumonia onset ≤8 days

Exclusion criteria

1. SaO2/SPO2≤94% on room air or Pa02/Fi02 ratio \<300mgHg before the onset of pneumonia 2. Severe liver disease (e.g. Child Pugh score ≥ C, AST\>5 times upper limit) 3. Patients with known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis,peritoneal dialysis) 4. Pregnant Or Lactating Women 5. Patients were eligible for organ transplantation or had undergone previous organ transplantation surgery 6. HIV infection 7. Had unstable angina or myocardial infarction within 30 days without vascular recanalization treatment

Design outcomes

Primary

MeasureTime frameDescription
upper respiratory infection or pneumonia or Sepsisup to 28 daysPatients were grouped and compared according to their diagnosis.

Secondary

MeasureTime frameDescription
Clinical statusdays 0, 3, 7assessed by Sequential Organ Failure Assessment
All cause mortalityup to 28 days
Length of hospital stay (days)up to 28 days
Length of ICU stay (days)up to 28 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026